Estradiol (2026): Doses, Side Effects, Forms & the Patch Shortage

Estradiol is one of the most prescribed medicines in the United States. ClinCalc's analysis of federal survey data ranked it the 52nd most prescribed drug in 2024, with about 12.9 million prescriptions for roughly 4.1 million people. Almost all of those are for menopause symptoms - and since the FDA moved to take the boxed warnings off hormone therapy in late 2025, demand has climbed again.

That popularity hides a lot of confusion. Women hear that estradiol is "natural" and "safe", or that it "causes cancer" and "makes you gain weight". They're told to try a patch, then find it's out of stock. They get a prescription for 1 mg and wonder whether that's a lot or a little. This guide answers those questions with the evidence: what estradiol does, how each form differs, what dose is normal, what the side effects and real risks are, what it costs, what to do about the patch shortage, and how to get a prescription - including online.

Who this guide is for: women in perimenopause or menopause who are considering estradiol, who've just been prescribed it, or who are already taking it and want to understand their options - including anyone whose pharmacy can't fill a patch prescription right now. It's also written for partners and family members trying to make sense of the headlines. Each section opens with a short, direct answer, followed by the detail and the sources behind it, so you can read just the parts you need.

Estradiol at a glance

Because the FDA changed hormone therapy's labels and demand jumped. In November 2025 the agency asked manufacturers to remove the boxed warnings on heart disease, breast cancer and probable dementia, and in February 2026 it approved the first updated labels. More women started estradiol, and estradiol patches - the most popular form - became hard to find in many pharmacies.

For more than two decades every estrogen product carried a black-box warning based on the 2002 Women's Health Initiative trial. That warning was written using results from women who were, on average, 63 when they started hormones - long after menopause - and it frightened a generation of women and doctors away from treatment. In November 2025, the FDA announced it would ask manufacturers to remove the boxed warnings about cardiovascular disease, breast cancer and probable dementia, and to add context about starting therapy closer to menopause. On February 12, 2026 it approved the first six updated labels, including Divigel (estradiol gel) and Estring (vaginal estradiol), with more following.

Two things did not change. The boxed warning about endometrial cancer stayed for systemic estrogen-alone products - which is why women with a uterus still need a progestogen - and the risks themselves didn't disappear; they're still described in the prescribing information. What changed is the framing: for healthy women under 60 or within 10 years of their last period, the Menopause Society and now the FDA describe the balance of benefits and risks as generally favorable.

The practical result was a surge in prescriptions, especially for transdermal estradiol, which most menopause specialists prefer. That surge is behind the supply problems described below. For the full history, see HRT's black box warning removed.

Yes, in practice - although it depends whose definition you use. Pharmacists' groups list estradiol patches in shortage, many brands and strengths are on back order or allocation, and women across the country report trouble filling prescriptions. The FDA acknowledged supply problems in September 2026 and said it was working with manufacturers, but as of early November it had not added estradiol patches to its official drug shortage list.

Here is what the record shows, as of November 9, 2026:

• The American Society of Health-System Pharmacists (ASHP) lists an active shortage of estradiol transdermal systems, with several manufacturers reporting back orders or allocation for specific strengths. ASHP updates the listing as manufacturers report changes.
• The FDA told reporters in September that it was working with manufacturers to increase supply. It had earlier said patches "remain available" even if particular brands vary by pharmacy, and FDA Commissioner Marty Makary attributed the strain to a large rise in demand after the label change, according to NBC News. You can check its drug shortage database for the official status.
• Manufacturers have described demand as unprecedented. Reporting from local news outlets in November describes women calling several pharmacies, being switched between brands and strengths, or going without.

The shortage is uneven. One pharmacy may have the twice-weekly 0.05 mg patch but not the weekly one; another may have a different manufacturer's version of the same strength. Generic patches with the same dose and schedule are interchangeable for most women, and so are many brands - so the first step is usually just asking the pharmacist what they can get.

Don't stop suddenly and don't cut patches unless your prescriber says the product allows it. Ask the pharmacist which strengths, brands and schedules they can get; ask your prescriber to switch you to an equivalent dose of another patch, an estradiol gel or spray, or estradiol tablets; and plan refills a week or two early while supply is tight.

Your options, from least to most change

A few cautions. Switching from a patch to tablets isn't a simple one-to-one swap for every woman: oral estradiol passes through the liver first, which changes clotting proteins and how much estradiol reaches your blood. If you were prescribed a patch specifically because of migraine with aura, a past clot, high triglycerides or liver problems, ask your prescriber before moving to pills. And keep taking your progestogen if you have a uterus, whatever estrogen form you switch to.

If you run out entirely, symptoms usually return gradually over days to weeks rather than overnight. A gap of a few days is not dangerous, but you may notice hot flashes, poor sleep or irregular bleeding. Report any unexpected bleeding once you restart. For how the routes compare in detail, see our estrogen patch vs pill guide.

Nobody can say for sure. Manufacturers have reported back orders on some strengths with estimated recovery dates, others are allocating supply, and the FDA has said it's working with makers to raise production. But demand for estradiol rose sharply after the label change and may stay high, so patchy availability could continue into 2027.

Drug shortages usually ease when manufacturers expand production lines or new suppliers enter the market, and both take months. In the meantime, availability varies by strength, brand and region week to week. Practical steps while supply is tight:

• Refill early. Request refills a week or two before you run out, and ask your pharmacy to order ahead if they're short.
• Be flexible on brand and schedule. Ask your prescriber to write the prescription so a pharmacist can substitute an equivalent generic, or to note an acceptable alternative strength or schedule.
• Ask for a 90-day supply if your insurance allows it, once you're settled on a dose.
• Check more than one pharmacy, including independent and mail-order pharmacies, which may source from different wholesalers.
• Have a backup plan agreed with your prescriber - for example, an equivalent gel dose - so you aren't scrambling when a refill fails.

For the current status of each product, the ASHP shortage page is updated as manufacturers report changes. Be wary of websites selling patches "without a prescription" during the shortage.

In menopause care, estradiol treats moderate to severe hot flashes and night sweats, treats vaginal dryness and painful sex, and helps prevent osteoporosis. It's also used to replace hormones in women whose ovaries stop working early, and in other settings such as gender-affirming care.

The FDA-approved uses for estradiol products vary by brand and form, but for menopause they fall into four groups:

• Vasomotor symptoms. Hot flashes and night sweats are the main reason women take systemic estradiol. Estrogen is still the most effective treatment: a Cochrane review of 24 placebo-controlled trials found oral hormone therapy cut weekly hot-flash frequency by about 75% compared with placebo, and reduced severity too.
• Genitourinary syndrome of menopause. Vaginal dryness, burning, pain with sex and some urinary symptoms respond to estradiol. Low-dose vaginal products are usually enough and are absorbed very little - see our vaginal estrogen guide.
• Bone protection. Estradiol is approved to help prevent postmenopausal osteoporosis. In the WHI, hormone therapy reduced hip and other fractures.
• Hypoestrogenism. Women with premature ovarian insufficiency, surgical menopause or other causes of low estrogen before the usual age of menopause are generally advised to take estrogen at least until around 51, the average age of natural menopause.

Estradiol also helps symptoms that many women don't connect to hormones: sleep disrupted by night sweats, joint aches, low mood linked to the transition, and skin dryness. The evidence for these is less direct than for hot flashes, and estradiol is not approved to prevent heart disease or dementia. Our hot flashes treatment guide ranks estradiol against every other option, including non-hormonal medicines.

Estradiol binds to estrogen receptors found throughout the body - in the brain's temperature-control center, the vagina and bladder, bone, blood vessels, skin and breast. Replacing the estradiol your ovaries no longer make restores those signals, which is why one hormone affects so many symptoms.

Before menopause, the ovaries produce estradiol in a monthly rhythm. During perimenopause that output becomes erratic - spiking and crashing - and after the final period it falls to a fraction of earlier levels. The body still makes a little estrogen, mostly estrone produced in fat tissue, but much less of the potent estradiol.

Several of the best-known symptoms follow directly from that drop:

• Hot flashes and night sweats. Falling estrogen changes signalling in the hypothalamus, the brain region that controls body temperature. Neurons that use a messenger called neurokinin B become overactive, narrowing the range of temperatures the body tolerates. Small rises in core temperature then trigger flushing and sweating. Estradiol calms that circuit - and the newer non-hormonal drugs target the same pathway from a different angle.
• Vaginal and urinary changes. The tissues of the vagina, vulva and urethra depend on estrogen to stay thick, elastic and moist. Without it, they thin and become fragile and dry.
• Bone loss. Estrogen restrains the cells that break down bone. When it falls, bone turnover speeds up and density drops fastest in the first years after menopause.
• Sleep and mood. Estrogen interacts with serotonin and other brain chemicals, and night sweats fragment sleep, which affects mood and concentration.

The route matters because of where estradiol goes first. Swallowed estradiol is processed by the liver, which converts much of it to estrone and changes the liver's output of proteins. Estradiol absorbed through the skin enters the general circulation directly, producing a ratio of estradiol to estrone closer to the premenopausal pattern.

Estrogen is a family of hormones; estradiol is the strongest and most important member. Your body makes three main estrogens - estradiol, estrone and estriol. "Estrogen" on a prescription can mean estradiol, conjugated estrogens such as Premarin, or other products, so it's worth knowing which one you're getting.

Why it matters: most of the modern evidence on transdermal therapy and blood clots is about estradiol, and a large UK study in the BMJ found oral conjugated estrogens carried a higher clot risk than oral estradiol. Estradiol is also the hormone measured in blood tests, so it's easier to check absorption when needed. For most women starting HRT today, estradiol is the default estrogen.

Both relieve hot flashes and protect bone. Estradiol is now more widely used because it's bioidentical, comes in transdermal forms, is cheaper as a generic, and - in a large UK study - oral estradiol carried a lower blood-clot risk than oral conjugated estrogens such as Premarin. Women doing well on Premarin don't need to switch.

Premarin (conjugated equine estrogens) is a mixture of estrogens derived from pregnant mares' urine. It was the estrogen used in the Women's Health Initiative, so much of the long-term trial evidence - good and bad - comes from it. It's available as tablets and a vaginal cream, and combined with a progestin (Prempro) or with bazedoxifene (Duavee), a combination that protects the womb lining without a progestogen.

Switching between the two is straightforward with a prescriber's guidance; approximate equivalents (for example 0.625 mg conjugated estrogens and 1 mg oral estradiol) are listed in the Canadian Menopause Society table.

Yes. Estradiol is chemically identical to the estradiol your ovaries make, so FDA-approved estradiol pills, patches, gels, sprays and vaginal products are all bioidentical. "Bioidentical" doesn't mean compounded, and compounded hormones aren't safer or more natural than approved ones.

Much of the marketing around "bioidentical hormone replacement therapy" implies that only custom-mixed creams, troches or pellets are bioidentical. That's not true. Brands such as Estrace, Climara, Vivelle-Dot, Divigel, EstroGel, Evamist, Vagifem and the estradiol-plus-progesterone capsule Bijuva all contain bioidentical hormones, and they've been tested for consistent dosing and safety.

Compounded hormones are made by pharmacies for individual patients and aren't FDA-approved. The FDA notes that compounded bioidentical hormone products haven't been reviewed for safety, effectiveness or quality, and that doses can vary from batch to batch. They can make sense in specific situations - for example, an allergy to an ingredient in every approved product - but they're not a better default. Hormone pellets implanted under the skin are a particular concern because the dose can't be adjusted or removed once placed. Our bioidentical hormones guide lists every FDA-approved option.

Estradiol comes in more forms than any other menopause hormone: tablets taken by mouth; patches, gels and a spray absorbed through the skin; vaginal creams, tablets, inserts and rings; and combination products that pair estradiol with a progestogen. Systemic forms treat whole-body symptoms; low-dose vaginal forms treat only local symptoms.

Brand availability changes, especially for patches in 2026, and not every strength is stocked everywhere. Injectable estradiol (valerate or cypionate) exists but isn't a standard choice for menopause because levels rise and fall sharply between doses. The next sections look at each main route in more detail.

Oral estradiol is the oldest, cheapest and most widely stocked form. Generic tablets come in 0.5 mg, 1 mg and 2 mg and are taken once a day. They work well for hot flashes and are easy to adjust - you can split a dose between two tablets, or move up or down a strength.

The trade-off is the liver. Swallowed estradiol is absorbed from the gut and passes through the liver before reaching the rest of the body. This "first-pass" effect converts much of it to estrone and raises the liver's production of clotting factors, triglycerides and sex-hormone-binding globulin. That's why pills are linked to a higher risk of blood clots and stroke than skin routes in observational studies (see the safety section below), and why oral estrogen can raise triglycerides and the dose of thyroid hormone some women need.

Good fit for: healthy women without clot risk factors who want the simplest, cheapest option; women whose skin reacts to patches; anyone during patch shortages who has been cleared by their prescriber. Less ideal for: women with a history of blood clots, migraine with aura, high triglycerides, gallbladder disease, obesity with other clot risk factors, or smokers.

Take the tablet at the same time each day, with or without food. If nausea is a problem, taking it with an evening meal often helps.

An estradiol patch is a thin adhesive square that releases a steady dose through the skin. Twice-weekly patches (changed every three to four days) and weekly patches deliver doses from about 0.025 mg (25 mcg) to 0.1 mg (100 mcg) per day. Because the hormone goes straight into the bloodstream, it bypasses the liver's first pass, keeps blood levels steadier than a daily pill, and - in observational studies - doesn't raise blood-clot risk.

That profile is why many menopause specialists prefer patches as a first choice, especially for women over 60, women with migraine, higher BMI or other clot risk factors. It's also why patches have been hardest hit by the 2026 demand surge.

Common patch problems are practical rather than medical:

• Skin irritation - redness or itching under the patch. Rotating sites, letting the skin dry fully and trying a different brand's adhesive usually helps.
• Patches falling off - after showers, swimming, sweating or friction from waistbands. Apply to clean, dry skin with no lotion, press firmly for about 10 seconds, and avoid the waistline.
• Uneven symptom control - some women notice symptoms creep back on the last day before a change. Switching from weekly to twice-weekly, or adjusting the dose, can help.

Apply patches to the lower abdomen or buttocks, never to the breasts. Use a new site each time and wait about a week before reusing the same spot. Avoid long hot baths, saunas and heating pads directly over the patch, which can increase absorption for a short time.

Gels and sprays are the other skin routes. You apply a measured dose once a day to the arms, shoulders or thighs (depending on the product), let it dry, and the estradiol is absorbed over the following hours. Like patches, they bypass the liver's first pass.

• EstroGel is a pump; each press delivers a fixed amount of 0.06% gel.
• Divigel comes in single-dose packets of different strengths, which makes it easy to fine-tune the dose.
• Evamist is a spray applied to the inside of the forearm.

Gels suit women who can't tolerate patch adhesive or who want to adjust their dose in small steps. The downsides are daily application, waiting for the gel to dry before dressing, and transfer: estradiol can pass to anyone who touches the treated skin. The Evamist label specifically warns about children and pets being exposed. Wash your hands after applying, cover the area with clothing once dry, and avoid skin-to-skin contact on that spot for a few hours.

"Estradiol cream" usually means one of two very different things. Estrace vaginal cream is an FDA-approved product for vaginal symptoms. Some online services also offer compounded estradiol body creams applied to the skin for systemic effect; these aren't FDA-approved, and absorption can vary. Ask which one you're being prescribed.

Low-dose vaginal estradiol - a cream, a small tablet or insert, or a soft ring - treats vaginal dryness, irritation, pain with sex and some urinary symptoms directly at the source. The doses are tiny compared with systemic HRT, blood levels stay in or near the postmenopausal range, and it doesn't need a progestogen for endometrial protection in most women.

Vaginal estradiol is one of the most underused treatments in menopause care. Unlike hot flashes, genitourinary symptoms usually get worse over time rather than better, and they respond well to treatment within a few weeks. It can be used on its own or added to systemic estradiol if vaginal symptoms persist.

Because it's so different from pills and patches, we cover it in a separate guide: vaginal estrogen - cream vs tablet vs ring, safety and cost. One note here: the Femring ring is the exception - it releases a systemic dose and does need a progestogen if you have a uterus.

No form is best for everyone. For most healthy women under 60, pills, patches and gels all work about equally well for hot flashes. Patches and gels are generally preferred if you have clot or stroke risk factors, migraine with aura, high triglycerides or are over 60; pills are cheapest and easiest to find; vaginal estradiol is best when the only symptoms are vaginal or urinary.

Your clinician will also weigh your symptoms, other medicines, preferences and cost. If the first form doesn't suit you, switching is common and usually straightforward.

Typical starting doses are 0.5-1 mg of oral estradiol a day, or a patch delivering 25-50 mcg (0.025-0.05 mg) a day. Doses are then adjusted to control symptoms - most women end up between 0.5 and 2 mg by mouth or a 25-100 mcg patch. The guiding principle is the lowest dose that works for you, for as long as you need it.

Because estradiol comes in so many forms, it helps to know roughly how doses line up. This table follows the Canadian Menopause Society equivalency table, a consensus guide clinicians use when switching routes:

These are approximate. Sources disagree at the edges - some put 2 mg oral closer to a 100 mcg patch - and absorption varies between women. Ultra-low-dose products are not interchangeable with standard doses. Treat the table as a starting point for a conversation, not a conversion you make yourself.

Younger women with premature ovarian insufficiency or surgical menopause often need higher doses than women in their 50s to control symptoms and protect bone. Women starting after 60 are usually started low, by the transdermal route.

Pills are written in milligrams (mg) per tablet, taken daily. Patches are written in milligrams per day released - so 0.05 mg/day is the same as 50 micrograms (mcg) a day - with a schedule of once or twice weekly. Gels are written as a number of pumps or a packet strength per day.

Mixing up units is a common source of confusion, especially when switching routes during the shortage. Some examples:

The number on a patch is not comparable to the number on a pill: a 0.05 mg patch is roughly equivalent to a 1 mg tablet, not a twentieth of it, because the patch delivers estradiol directly into the blood every day without liver breakdown. If a new prescription looks very different from your old one, ask the pharmacist to confirm before you start.

Most women notice fewer and milder hot flashes within two to four weeks, with the full effect by about three months. Lower doses can take six to eight weeks. Vaginal symptoms improve over several weeks to three months. Sleep often improves early, as night sweats settle.

Clinical trials of estrogen are designed to show a clear drop in hot flashes by week four, and they usually do: in one placebo-controlled trial, estradiol 1 mg roughly halved moderate-to-severe hot flashes by week four. Across trials, the Cochrane review found about a 75% reduction in weekly frequency compared with placebo.

Most guidance suggests reviewing how you feel after about three months before deciding a dose isn't working. If symptoms are still troublesome then, the usual next steps are a higher dose, a different route (some women absorb patches poorly), or checking whether something other than menopause is driving the symptoms.

Expect gradual improvement rather than an overnight change. Many women sleep better and have fewer night sweats within the first few weeks, notice clearer improvement in hot flashes by about a month, and reach the full effect by three months. Early side effects such as breast tenderness and spotting usually fade over the same period.

Keeping a simple symptom diary - hot flashes per day, nights woken, mood, bleeding - makes the three-month review far more useful. It shows your clinician whether the dose is right, whether a different route might suit you better, and whether any remaining symptoms are likely to be hormonal at all.

If you feel no difference at all after three months on a standard dose, that's worth investigating rather than simply increasing the dose: poor absorption from a patch or gel, a dose that's still too low, or symptoms with another cause - thyroid problems, anemia, sleep apnea, depression or medication side effects - are all possibilities.

Yes, if you still have a uterus. Estradiol on its own stimulates the lining of the womb and raises the risk of endometrial hyperplasia and cancer; a progestogen prevents that. If you've had a hysterectomy, you usually take estradiol alone. Low-dose vaginal estradiol generally doesn't need a progestogen.

The most common pairing today is micronized progesterone (Prometrium or generics), a bioidentical progesterone taken by mouth - either every night (continuous) or for 12-14 days a month (cyclical, which usually brings a monthly bleed). Other options include synthetic progestins in combination products and a levonorgestrel IUD, which protects the lining locally and also provides contraception.

The choice of progestogen also matters for breast cancer risk and side effects: observational data suggest micronized progesterone may carry less breast cancer risk than some synthetic progestins, though it's not risk-free. Our progesterone guide covers doses, side effects and what to expect.

On cyclical HRT, a monthly withdrawal bleed is expected. On continuous combined HRT, irregular spotting is common for the first three to six months and then usually stops. Bleeding that is heavy, keeps going beyond six months, starts after you've had no bleeding, or happens after sex should be checked.

Bleeding is one of the main reasons women stop HRT early, often unnecessarily. Knowing what to expect helps:

Checking usually means a pelvic ultrasound to look at the thickness of the womb lining, and sometimes a biopsy. Most of the time the cause is benign - the regimen simply needs adjusting, often with a higher progestogen dose or a switch from continuous to cyclical - but bleeding can occasionally be a sign of endometrial hyperplasia or cancer, which is why it shouldn't be ignored.

The most common side effects are breast tenderness, headache, spotting or irregular bleeding, nausea and bloating. They're usually mild and often ease within the first two to three months. Patches can also irritate the skin. Serious side effects - blood clots, stroke, gallbladder problems - are uncommon but need urgent attention.

Exact rates depend on the product and dose. Two FDA labels give a sense of scale:

• For a twice-weekly estradiol patch (Vivelle), the most common adverse reactions, each in at least 5% of users, were headache, breast tenderness, back pain, limb pain, nasopharyngitis (cold symptoms) and indigestion.
• For the estradiol-plus-progesterone capsule, the most common reactions (at least 3% and more than placebo) were breast tenderness, headache, nausea, vaginal bleeding, vaginal discharge and pelvic pain - breast tenderness affected about 10% of women in one trial table.

Common side effects and what helps

Get urgent help for

• Pain, swelling or warmth in one leg, or sudden shortness of breath or chest pain (possible blood clot).
• Sudden severe headache, weakness or numbness on one side, trouble speaking or seeing (possible stroke).
• Yellowing of the skin or eyes, or severe upper abdominal pain.
• A new breast lump, or heavy or persistent bleeding.

Many early side effects are a sign the dose is a little high for you, or that your body is adjusting. Stopping isn't the only option - a lower dose, a different route or a different progestogen fixes most of them.

Good trial evidence says no. A Cochrane review of 28 randomized trials with about 28,500 women found no evidence that estrogen alone or estrogen plus a progestogen adds weight beyond what women typically gain around menopause. Weight gain in midlife is real, but it's driven mainly by age, sleep, activity and the menopause transition itself - not by HRT.

This is one of the most common reasons women hesitate to start estradiol, so the evidence is worth spelling out. A 2026 clinical review of hormone therapy and weight summarised the Cochrane analysis: across 28 randomized trials involving 28,559 women, neither estrogen-alone nor combined therapy influenced body weight beyond the usual menopausal gain. It also found no evidence that HRT prevents that gain. A later meta-analysis of newer trials reached a similar conclusion for most regimens.

Why do so many women feel they gained weight on HRT, then? A few reasons:

• Timing. HRT is usually started during the years when weight gain is most common anyway, so it gets the blame.
• Fluid retention and bloating in the first weeks - often from the progestogen - can show on the scale but isn't fat.
• Body-fat distribution. Falling estrogen shifts fat toward the abdomen. Some studies suggest hormone therapy may limit that central shift, even if total weight doesn't change much.

If weight is a major concern, the bigger levers are sleep, strength training, protein intake and, for some women, medical weight management. Our guide to GLP-1 medicines and menopause covers how those fit alongside HRT.

Oral estradiol modestly raises the risk of blood clots in the legs and lungs; estradiol through the skin (patch, gel or spray) does not appear to, in large observational studies. The absolute risk for a healthy woman in her 50s is low either way, but route matters most for women with clot risk factors.

The strongest evidence comes from two sources:

• The French ESTHER study and later analyses found that oral but not transdermal estrogen increased venous thromboembolism (VTE) risk in postmenopausal women.
• A large UK BMJ study by Vinogradova and colleagues (2019), using two primary-care databases, found oral HRT was associated with higher VTE risk - about 40% higher for estrogen alone and around 70% higher for oral estrogen plus progestin, according to commentary on the study - while transdermal estradiol was not associated with increased risk (relative risk close to 1). Oral estradiol carried less risk than oral conjugated estrogens.

These are observational studies, not randomized trials, so they can't prove cause. But the biology fits: oral estrogen passing through the liver increases clotting factors, while transdermal estradiol has minimal effect on them. That's why guidelines generally prefer transdermal estradiol for women with a higher baseline risk - higher BMI, a past clot, smokers, older women, and those with certain clotting disorders (who may not be able to take systemic estrogen at all).

Stroke follows a similar pattern: the WHI found a small increase with oral hormones, mostly in older women, and observational data suggest low-dose transdermal estradiol doesn't raise stroke risk. Women with migraine with aura are usually steered toward skin routes for this reason.

Estradiol taken alone - by women without a uterus - carries little or no added breast cancer risk. Combined with a progestogen, systemic HRT slightly raises the chance of breast cancer with longer use. Low-dose vaginal estradiol hasn't been linked to breast cancer.

The best estimate of size comes from the 2019 Lancet meta-analysis of 58 studies. It found that five years of daily combined HRT starting at 50 led to about one extra breast cancer for every 50 users over the following 20 years, and estrogen alone to about one extra case for every 200 users. In the WHI randomized trial of estrogen alone, women actually had fewer breast cancers than those on placebo.

Several factors change the picture: the type of progestogen (micronized progesterone may carry less risk than some synthetic progestins), how long HRT is used, and your own baseline risk - family history, alcohol, weight and breast density matter too. For many women, the risk linked to HRT is smaller than the risk linked to obesity or drinking two or more alcoholic drinks a day.

Women who've had breast cancer usually aren't offered systemic estradiol, though some may be able to use low-dose vaginal estradiol after discussion with their oncologist. Our HRT and breast cancer guide walks through the numbers in detail.

Estradiol clearly protects bones and is approved to prevent osteoporosis. Its effects on the heart and brain depend on when it's started: starting near menopause appears neutral to favorable for the heart, while starting many years later can increase risk. It isn't approved to prevent heart disease or dementia.

• Bones. Estrogen slows the rapid bone loss that follows menopause. In the WHI, hormone therapy reduced hip, vertebral and other fractures. For women at high fracture risk who also have menopause symptoms, estradiol can do double duty.
• Heart. The "timing hypothesis" holds that estrogen started in early menopause, while arteries are still healthy, doesn't harm and may benefit the heart, whereas starting in women 10 or more years past menopause may increase cardiovascular events. Long-term WHI follow-up and later analyses support a more favorable picture for younger starters, which is one reason the FDA removed the boxed warning on cardiovascular disease.
• Brain. The WHI Memory Study found more dementia in women who started hormones at 65 or older. There's no good evidence that estradiol prevents dementia in younger women, and it shouldn't be taken for that purpose - but it can help brain fog and sleep linked to hot flashes.

The Menopause Society's 2022 position statement summarises it this way: for women under 60 or within 10 years of menopause without contraindications, the benefits of hormone therapy generally outweigh the risks for treating bothersome symptoms and preventing bone loss.

Often, yes - mainly when those symptoms are driven by hot flashes and night sweats. Estradiol reliably improves sleep disrupted by night sweats, and many women report better mood and concentration once they sleep again. It isn't a treatment for depression on its own, but it can help low mood that emerges during perimenopause.

Sleep problems are among the most common menopause complaints, and night sweats are a major cause: waking several times a night soaked and overheated leaves anyone exhausted, irritable and foggy. Because estradiol is the most effective treatment for night sweats, it's often the most effective sleep treatment for women in this situation. Micronized progesterone taken at bedtime has a mild sedative effect that some women find helpful too.

Mood is more complicated. The perimenopausal years carry a higher risk of new or recurring depression, especially for women with a history of depression, premenstrual mood symptoms or postpartum depression. Some studies suggest transdermal estradiol can improve depressive symptoms in perimenopausal women, though the evidence is less consistent for women after menopause. If you have significant depression or anxiety, estradiol may be part of the plan but shouldn't replace proper mental health treatment.

"Brain fog" - trouble finding words, poor concentration, forgetfulness - is real and common in perimenopause, and it usually improves over time. For most women it reflects disrupted sleep and fluctuating hormones rather than lasting cognitive decline. Estradiol may help indirectly by improving sleep and hot flashes. There's no evidence it prevents dementia, and it shouldn't be started for that reason.

Estradiol can help skin dryness and some joint aches, and it makes sex more comfortable by treating vaginal dryness. Its effect on hair is modest and inconsistent. For low sexual desire specifically, estradiol helps some women but not all; testosterone is the treatment with the most evidence for desire.

• Skin. Estrogen supports collagen and skin moisture, and collagen falls quickly in the first years after menopause. Some women notice their skin feels less dry on estradiol. It's not approved for skin aging, and the effect is gradual.
• Joints. Aches and stiffness are common around menopause. In the WHI, women taking estrogen reported less joint pain than those on placebo, though the evidence isn't strong enough to use estradiol mainly for joint symptoms.
• Hair. Thinning hair has many causes - genetics, thyroid, iron, stress and androgens. Estradiol may help a little in some women, but it's not a reliable hair treatment, and some progestins can worsen hair thinning.
• Sex. Vaginal dryness and pain with sex respond well to estradiol, either systemic or vaginal. Desire is influenced by many factors - relationship, mood, sleep, body image - and estrogen alone often doesn't restore it. For women with persistent distressing low desire, testosterone has the best evidence; see our testosterone for women guide.

Usually, yes. Many women with migraine can use estradiol safely, and some find their headaches improve once hormone levels are steadier. Transdermal estradiol at a standard dose is generally preferred, especially for migraine with aura, because pills cause bigger swings in levels and carry a higher stroke concern.

Migraine often worsens in perimenopause, when estrogen levels rise and fall unpredictably; the drop in estrogen is a well-known trigger. After menopause, when levels are low but stable, many women find migraines improve. Estradiol can help or hinder depending on how it's delivered: steady patch or gel levels tend to help, while fluctuating levels can trigger attacks.

Migraine with aura is linked to a higher baseline risk of stroke, and combined hormonal birth control - which contains much stronger ethinyl estradiol - is generally avoided in women with aura. Menopausal estradiol is a much lower dose, and transdermal estradiol isn't thought to add meaningfully to stroke risk at standard doses, so many specialists consider it acceptable. If you develop new or worsening migraine with aura after starting estradiol, report it promptly.

Systemic estradiol generally isn't used if you have unexplained vaginal bleeding, current or past breast cancer or another estrogen-sensitive cancer, a current or past blood clot, a previous stroke or heart attack, active liver disease, a known clotting disorder, or if you might be pregnant. Some of these may still allow low-dose vaginal estradiol.

The FDA labels for estradiol list these contraindications:

• Undiagnosed abnormal genital bleeding
• Known, suspected or past breast cancer (except in specific treatment settings)
• Known or suspected estrogen-dependent cancer
• Active or past deep vein thrombosis or pulmonary embolism
• Active or recent arterial disease, such as stroke or heart attack
• Liver dysfunction or disease
• Known protein C, protein S or antithrombin deficiency, or other known clotting disorders
• Known or suspected pregnancy
• Allergy to any ingredient

Other conditions call for caution rather than a flat no: high blood pressure that isn't controlled, migraine with aura, gallbladder disease, high triglycerides, endometriosis, fibroids, lupus, and a strong family history of breast cancer. In many of these, a transdermal route, a lower dose or closer monitoring makes estradiol reasonable. Women who can't take estrogen have effective non-hormonal options - see our hot flashes treatment guide.

The most important interactions are with drugs that speed up estradiol's breakdown - such as St John's wort, carbamazepine, phenytoin and rifampin - which can make it less effective, and with thyroid hormone, whose dose may need to rise when you start oral estradiol. Always tell your prescriber about every medicine and supplement you take.

Alcohol doesn't interact directly with estradiol, but regular drinking independently raises breast cancer risk, which adds to any risk from HRT.

Usually, yes. Well-controlled high blood pressure, type 2 diabetes and thyroid disease don't rule out estradiol. Transdermal estradiol is often preferred in women with cardiovascular risk factors, and thyroid hormone doses may need adjusting after starting oral estradiol.

• High blood pressure. Standard-dose estradiol doesn't generally raise blood pressure, and transdermal estradiol has a neutral effect. Uncontrolled hypertension should be treated first, because it independently raises stroke risk.
• Diabetes. Estrogen doesn't worsen blood sugar control and may modestly improve insulin sensitivity. Because diabetes increases cardiovascular risk, clinicians often favor a transdermal route and pay close attention to timing and overall risk.
• Thyroid disease. Oral estradiol increases thyroid-binding globulin, so women on levothyroxine may need a higher dose; a thyroid test a couple of months after starting is common. Transdermal estradiol has little effect on this.
• High cholesterol. Oral estradiol lowers LDL and raises HDL but can raise triglycerides; transdermal estradiol has smaller effects on lipids and doesn't raise triglycerides.
• Higher body weight. Obesity raises clot risk, so a transdermal route is usually preferred.

In all of these, the decision depends on your overall cardiovascular risk and how long it's been since your last period, not on one condition alone.

Often, yes, with care. Fibroids usually shrink after menopause and standard-dose HRT rarely makes them grow much, though they should be monitored. Women with a history of endometriosis are usually advised to take a progestogen with estradiol - even after a hysterectomy - to lower the small risk of endometriosis reactivating.

Both conditions are estrogen-sensitive, which is why they often improve once natural estrogen falls. Menopausal estradiol doses are much lower than the levels of the reproductive years, so most women with a history of either condition can still be treated:

• Fibroids. If you notice new pelvic pressure, pain or heavy bleeding on HRT, an ultrasound can check whether fibroids have grown. Transdermal estradiol and a levonorgestrel IUD are common choices.
• Endometriosis. Combined therapy (estradiol plus a progestogen) is generally preferred over estrogen alone, because residual endometriosis tissue can be stimulated by unopposed estrogen. Recurrence is uncommon but possible, so new pelvic pain should be reported.

Adenomyosis, endometrial polyps and a history of endometrial hyperplasia also call for a tailored plan and closer follow-up.

Take pills at the same time daily. Put patches on clean, dry skin below the waist, rotate sites and change them on schedule. Apply gel or spray to the recommended area, let it dry and wash your hands. If you miss a dose, take or apply it when you remember unless the next one is nearly due - don't double up.

Practical tips by form

• Pills: Same time each day. Taking it with food or at bedtime can reduce nausea.
• Patches: Lower abdomen or buttocks; never on the breasts or waistline. Press firmly for about 10 seconds. If one falls off, reapply it or put on a new one, then keep your usual change day. Fold used patches sticky-side together before throwing away - they still contain hormone.
• Gel: Apply to the arm, shoulder or thigh as directed, not to the breasts or vaginal area. Let it dry for a few minutes before dressing; avoid swimming or showering for about an hour. Wash hands afterwards.
• Spray: Inside of the forearm; let it dry. Keep children and pets from touching the area.
• Vaginal products: Usually at bedtime; follow the starting and maintenance schedule on your prescription.

If you miss a dose

Usually not. In women over 45 with typical symptoms, menopause is diagnosed from symptoms and periods, not blood tests, and estradiol doses are adjusted to how you feel. Blood levels can help in specific cases - such as suspected poor absorption from a patch or gel, or premature ovarian insufficiency.

Estradiol levels swing widely in perimenopause, so a single test says little about whether you're "in menopause". Once you're on treatment, the goal is symptom relief at the lowest effective dose, not a target number. Clinicians may check a level if symptoms persist despite a reasonable transdermal dose (some women absorb patches or gels poorly), if you're young and on replacement doses, or if there's concern about very high levels.

Two cautions: saliva hormone tests aren't reliable for dosing and aren't recommended by menopause societies, and blood levels from gels can be misleading if blood is drawn from the arm where gel was applied. If a service insists on repeated hormone panels to "balance" your hormones, be skeptical - it's often a sign of a compounded-hormone business model.

Taking an extra tablet or wearing two patches by mistake isn't usually dangerous. You might notice nausea, breast tenderness, bloating or some vaginal bleeding. Go back to your normal dose and tell your prescriber if symptoms are bothersome. Large overdoses or a child swallowing estradiol need a call to poison control.

Signs that your regular dose may be a little too high include persistent breast tenderness, nausea, headaches, fluid retention, irritability or breakthrough bleeding. These usually settle with a dose reduction. In the US, Poison Control can be reached at 1-800-222-1222 if a child or pet swallows a tablet or chews a patch, or after any large accidental dose.

The opposite problem - a dose that's too low - shows up as hot flashes or night sweats that never fully settle, or symptoms returning before a patch change. That's a reason to discuss a dose or route change, not to add extra doses on your own.

Generic estradiol tablets are among the cheapest prescription medicines - from about $9 for a month's supply with a free discount card, and often a low copay with insurance. Generic patches and gels cost more, and brand-name products can run $100-$200 or more a month without coverage. Online menopause services add a consult or subscription fee on top of, or including, the medication.

Prices change often and vary by pharmacy, strength and coupon. These are approximate cash prices from GoodRx listings - check current prices for your exact prescription:

With insurance, generic estradiol tablets and patches are on most pharmacy formularies, and many Medicare Part D plans cover them. Brand-name gels and sprays are more likely to need prior authorization or carry higher copays.

Through an online menopause service, the total depends on the model: some bundle medication into a monthly price; others charge for the visit and send the prescription to your pharmacy. Our online HRT cost comparison works through real monthly and first-year totals for each provider.

Most insurance plans, including most Medicare Part D drug plans, cover generic estradiol tablets and patches, often at a low copay. Brand-name gels, sprays and combination products are more likely to need prior authorization or cost more. Plans differ, so check your formulary.

A few points that help keep costs down:

• Ask for generics. Generic estradiol tablets and patches are usually the lowest tier on drug formularies.
• Compare with a discount card. For inexpensive generics, a free discount card price is sometimes lower than an insurance copay.
• Check prior authorization for brand-name gels or sprays before your prescriber sends the prescription.
• Use HSA or FSA funds. Prescription estradiol is generally an eligible expense, and some online menopause services accept HSA and FSA cards for their fees.
• Medicare. Original Medicare Parts A and B don't cover outpatient drugs; you need a Part D plan or Medicare Advantage plan with drug coverage. Some online menopause clinics don't bill Medicare for visits.

For the visit itself, insurance coverage depends on the provider: some online clinics are in-network with commercial plans, while others are self-pay. Our online HRT cost guide compares them.

Estradiol is prescription-only in the US. You can get it from a primary care doctor, a gynecologist, a certified menopause practitioner, or a licensed online menopause service. Any of them should ask about your symptoms, periods and health history - especially clots, stroke, heart disease and cancer - before prescribing, and plan a follow-up.

Many women find it hard to get estradiol through traditional routes: appointments are weeks away, and some clinicians are still uneasy about HRT. Online menopause clinics have grown quickly to fill that gap. They differ mainly in how you meet a clinician, which estradiol forms they offer and how you pay:

During the patch shortage, a pharmacy-based service lets you fill wherever stock is available, while mail-order services depend on their own pharmacy partners' supply - ask before you sign up. Whatever route you choose, ask which product you'll receive and whether it's FDA-approved or compounded.

Our ranking of the 5 best online HRT clinics compares these services in depth, and how to get HRT online walks through the process step by step.

Ask which form and dose suits your health history, whether you need a progestogen and which one, what side effects to expect and when they should settle, when you'll be reviewed, and what to do if your pharmacy can't fill the prescription.

• Which route - pill, patch, gel or spray - is best for me, and why?
• What dose are we starting at, and how will we adjust it?
• Do I need a progestogen? Which one, and continuous or cyclical?
• Is this product FDA-approved or compounded?
• What bleeding is normal in the first months, and what should I report?
• How long until I should notice a difference, and when is my review?
• What happens if my pharmacy runs out - can we switch to an equivalent?
• Are any of my current medicines or supplements a problem?
• Do I need contraception as well? (Menopausal HRT is not birth control.)
• How long might I stay on it, and how will we decide when to stop?

Bring a list of your symptoms, the date of your last period, your blood pressure if you know it, and your personal and family history of clots, stroke, heart disease and cancer. That makes any appointment - in person or online - faster and safer.

Yes. Estradiol can be started in perimenopause, while periods are still happening, if symptoms are troublesome. It's usually paired with cyclical or continuous progesterone or a hormonal IUD. It doesn't work as contraception, so women who could still become pregnant need a separate method.

Perimenopause - often starting in the 40s - is when symptoms frequently peak: hot flashes, poor sleep, mood swings, heavier or irregular periods and brain fog, while hormone levels swing up and down. Waiting for periods to stop before treating isn't necessary.

Because your own estradiol is still fluctuating, perimenopausal women sometimes need dose adjustments, and bleeding patterns can be unpredictable at first. A levonorgestrel IUD plus estradiol is a popular combination: it controls heavy bleeding, protects the womb lining and provides contraception. Heavy, prolonged or very irregular bleeding should be checked before starting HRT. See our guides to HRT for perimenopause and perimenopause symptoms.

You can, but it's approached more cautiously. Starting systemic estradiol more than 10 years after menopause or after 60 carries higher risks of heart disease, stroke, clots and dementia than starting earlier, so clinicians usually choose a low transdermal dose, review the reasons carefully, and consider alternatives. Low-dose vaginal estradiol is fine to start at any age.

The age at which you start matters more than your current age. A woman who began estradiol at 52 and is doing well at 64 is in a very different situation from a woman starting for the first time at 64. For the first, the Menopause Society says there's no reason to stop routinely at 60 or 65 if benefits continue to outweigh risks, with yearly review. For the second, persistent severe hot flashes or high fracture risk may still justify treatment, but a patch or gel at a low dose is the usual choice.

Many women in their 60s and 70s benefit most from vaginal estradiol, since genitourinary symptoms tend to worsen with age and respond well to local treatment.

After a hysterectomy you can usually take estradiol on its own, without a progestogen. After surgical menopause (removal of both ovaries) or premature ovarian insufficiency before 40, estradiol is generally recommended at least until the average age of menopause - around 51 - to protect bones, the heart and quality of life, unless there's a reason not to.

Hysterectomy with ovaries kept. Your ovaries keep making hormones until natural menopause, though some women reach menopause a little earlier. Without periods, the only signs may be hot flashes or other symptoms. When you do need estradiol, you can take it alone - which is simpler and, based on the Lancet and WHI data, carries less breast cancer concern than combined therapy.

Surgical menopause. Removing both ovaries causes an abrupt drop in estradiol, and symptoms can be sudden and severe. Women who have this surgery before natural menopause are usually advised to start estradiol soon afterwards, unless they've had an estrogen-sensitive cancer. Some women who had endometriosis may be advised to take a progestogen as well.

Premature ovarian insufficiency (POI) and early menopause. Losing ovarian function before 40 (POI) or before 45 (early menopause) raises long-term risks of osteoporosis and cardiovascular disease. Here estradiol isn't just for symptoms - it replaces hormones the body would normally still be making. Doses are often higher than in typical menopause, and the risks seen in older women don't apply in the same way. Women with POI can occasionally still ovulate, so contraception may be needed.

Estradiol remains the most effective treatment for hot flashes. For women who can't or don't want to take estrogen, FDA-approved non-hormonal medicines - fezolinetant (Veozah), elinzanetant (Lynkuet) and low-dose paroxetine - plus off-label options such as venlafaxine and gabapentin offer meaningful but generally smaller relief.

For the full ranking - including lifestyle approaches, cognitive behavioral therapy and supplements - see how to stop hot flashes: every treatment ranked.

There's no fixed limit. Guidelines no longer recommend stopping at a set age or after five years; instead, women review the benefits and risks with their clinician at least yearly and continue as long as the benefits outweigh the risks. Many women take estradiol for several years; some continue into their 60s and beyond.

The old advice to use "the lowest dose for the shortest time" came from the early-2000s interpretation of the WHI. Current guidance is more individual. Reasons to keep going include persistent hot flashes, bone protection and quality of life; reasons to reconsider include a new diagnosis such as a clot or breast cancer, rising cardiovascular risk, or simply no longer needing it.

Breast cancer risk with combined HRT rises with duration, which is one factor in the yearly review. Estrogen-alone therapy, used after hysterectomy, carries much less of that concern.

You can stop gradually or all at once; over the long run, both approaches lead to similar rates of symptoms coming back. Many women prefer to taper over a few weeks or months to see whether symptoms return. About half of women notice some hot flashes again after stopping, so it's worth planning with your clinician.

There's no medical danger in stopping, but symptoms that estradiol was masking may reappear - especially if you stop within a few years of menopause. Common tapering approaches include stepping down to a lower patch or tablet strength, or lengthening the interval between doses, over a few months. If symptoms return and are troublesome, restarting is an option; so are non-hormonal treatments.

If you have a uterus, follow your clinician's advice on the progestogen as you stop, and report any bleeding that happens more than a few weeks after stopping. Bone density can fall again after stopping estrogen, so women at risk of osteoporosis should discuss bone protection.

Ask your surgeon and prescriber. Advice varies: many women continue estradiol through surgery with standard clot prevention, while some surgeons advise stopping oral estrogen a few weeks before major operations that involve long periods of immobility. Transdermal and low-dose vaginal estradiol are less of a concern.

Major surgery, long-haul travel and prolonged bed rest all raise clot risk on their own. Because oral estrogen adds to that risk, older guidance often recommended stopping HRT about four weeks before major surgery. More recent practice tends to weigh the extra risk against the downside of symptoms returning, and to manage it with clot prevention instead. Whatever you're advised, tell the surgical team you take estradiol and which form.

For long flights, the usual advice applies to everyone: walk around regularly, stay hydrated and consider compression stockings if you have other risk factors.

For most healthy women who start near menopause, yes - with yearly review. The main long-term considerations are a small increase in breast cancer with prolonged combined use, clot and stroke risk (lower with transdermal routes), and endometrial protection if you have a uterus. Bone protection is a long-term benefit.

"Safe" always means safe relative to something. For a woman with severe hot flashes and poor sleep, the benefits of treatment are large and immediate; the risks are small in absolute terms and depend heavily on age, route, dose and progestogen type. The table below summarises how estradiol's main long-term risks compare by route and regimen, based on the evidence discussed above.

For the full evidence review, read is HRT safe?

Decades of mixed messages have left a lot of myths around estradiol. Here's what the evidence says about the most common ones.

Estradiol works best alongside basics that independently ease menopause symptoms and lower long-term risk: not smoking, limiting alcohol, regular strength and aerobic exercise, good sleep habits, and managing blood pressure and weight. These also reduce the risks that HRT is often blamed for.

• Don't smoke. Smoking increases clot and stroke risk, speeds up the liver's breakdown of oral estradiol, and worsens hot flashes.
• Limit alcohol. Alcohol is an independent breast cancer risk factor and a common hot-flash trigger. Keeping to a few drinks a week reduces both.
• Strength training. Resistance exercise protects bone and muscle and helps with the central weight gain of midlife - something estradiol alone doesn't fix.
• Cool your bedroom and keep a regular sleep schedule; layered bedding helps on nights when hot flashes break through.
• Know your numbers. Blood pressure, cholesterol and blood sugar matter more for heart health after menopause than HRT does.
• Keep up screening. Mammograms and cervical screening continue on the usual schedule while you take estradiol.

Store estradiol at room temperature, away from heat and moisture. Patches should stay sealed in their pouches until use. If you're travelling, pack enough for the trip plus a few days' extra in your hand luggage - especially while patches are hard to find.

No. In the US, estradiol is prescription-only in every form. Products sold without a prescription as "estrogen creams", "natural progesterone" or "hormone balance" supplements either contain no estradiol or aren't regulated as medicines.

Online sellers that ship estradiol without a clinician's assessment are operating outside US law and may sell counterfeit or mislabeled products. If cost or access is the barrier, a low-cost telehealth consult plus a generic prescription filled with a discount card is usually cheaper than people expect - and far safer. You can check that an online pharmacy is licensed through your state board of pharmacy.

Estradiol is the backbone of modern menopause treatment: bioidentical, FDA-approved, effective for hot flashes, night sweats and vaginal symptoms, and protective for bones. The 2025-2026 label changes reflect what menopause specialists have said for years - for healthy women who start near menopause, the benefits usually outweigh the risks.

The details still matter. Choose the route that fits your health: patches and gels for women with clot or stroke risk factors, pills when cost and availability come first, vaginal estradiol for local symptoms. Take a progestogen if you have a uterus. Expect some early side effects and give it about three months. Review it every year. And during the 2026 patch supply squeeze, plan refills early and ask about equivalent alternatives rather than going without.

If you're ready to talk to someone, compare the best online HRT clinics or start with your own doctor. This guide is general information, not medical advice - your clinician can tailor estradiol to your history and goals.

This guide was written by the HRT Women editorial team and is based on primary sources wherever possible: FDA prescribing information and announcements, the Menopause Society's 2022 position statement, Cochrane systematic reviews, the Women's Health Initiative trials, the 2019 Lancet breast cancer meta-analysis, and large observational studies on blood-clot risk by route. Where we cite secondary summaries - for example, of the Cochrane body-weight review or of drug prices - we say so, and prices are labelled as approximate.

Shortage information reflects the ASHP listing, FDA statements and news reporting available on November 9, 2026; it changes quickly, so check the linked sources for the latest status. Provider details come from our reviews of each service and are rechecked when we update them. We earn commissions from some providers mentioned on this site; that doesn't change the evidence we report. This guide is general information and doesn't replace advice from your own clinician.